Evidence map›Paper›PMID 31514402›Full record

ArticleJournal of clinical medicine2019

Clinical Infections by Herpesviruses in Patients Treated with Valproic Acid: A Nested Case-Control Study in the Spanish Primary Care Database, BIFAP.

Miguel Gil, Rocío González-González, Angela Vázquez-Calvo, Arturo Álvarez-Gutiérrez, Miguel A Martín-Acebes, Beatriz Praena, Raquel Bello-Morales, Juan-Carlos Saiz, Jose A López-Guerrero, Enrique Tabarés and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Miguel GilBIFAP, Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Agency for Medicines and Medical Devices (AEMPS), 28022 Madrid, Spain. mgilg@aemps.es.
Rocío González-GonzálezBIFAP, Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Agency for Medicines and Medical Devices (AEMPS), 28022 Madrid, Spain. rogogo@gmail.com.
Angela Vázquez-CalvoCentro de Biología Molecular Severo Ochoa (CSIC-UAM), Nicolás Cabrera 1, 28049 Madrid, Spain. angelavazquezcalvo@gmail.com.
Arturo Álvarez-GutiérrezBIFAP, Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Agency for Medicines and Medical Devices (AEMPS), 28022 Madrid, Spain. aalvarez_externo@aemps.es.
Miguel A Martín-AcebesDepartment of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INA), 28040 Madrid, Spain. martin.mangel@inia.es.
Beatriz PraenaCentro de Biología Molecular Severo Ochoa (CSIC-UAM), Nicolás Cabrera 1, 28049 Madrid, Spain. bpraena@cbm.csic.es.
Raquel Bello-MoralesCentro de Biología Molecular Severo Ochoa (CSIC-UAM), Nicolás Cabrera 1, 28049 Madrid, Spain. raquel.bello-morales@inv.uam.es.
Juan-Carlos SaizDepartment of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INA), 28040 Madrid, Spain. jcsaiz@inia.es.
Jose A López-GuerreroCentro de Biología Molecular Severo Ochoa (CSIC-UAM), Nicolás Cabrera 1, 28049 Madrid, Spain. jal@cbm.uam.es.
Enrique TabarésUniversidad Autónoma de Madrid, Facultad de Medicina, Arzobispo Morcillo 4, 28029 Madrid, Spain. enrique.tabares@uam.es.
Francisco SobrinoCentro de Biología Molecular Severo Ochoa (CSIC-UAM), Nicolás Cabrera 1, 28049 Madrid, Spain. fsobrino@cbm.csic.es.
Centro de Biología Molecular Severo Ochoa · ESAgencia Española de Medicamentos y Productos Sanitarios · ESInstituto Nacional de Investigación y Tecnología Agraria y Alimentaria · ESUniversidad Autónoma de Madrid · ES

Funding

Spanish 341 Ministerio de Economía y Competitividad AGL2014-52395-C2-1-R and AGL2017-84097-C2-1-R
6 · The paper itself

Abstract

The objective of this study is to evaluate the risk of clinical infections by herpesviruses in patients exposed to valproic acid (VPA). We performed a case-control study nested in a primary cohort selected from the Spanish primary care population-based research database BIFAP (Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria) over the period 2001-2015. The events of interest were those diseases caused by any herpesviruses known to infect humans. For each case, up to 10 controls per case matched by age, gender, and calendar date were randomly selected. A conditional logistic regression was used to compute adjusted odds ratios (OR) and their 95% confidence intervals (95% CI). Current use of VPA was associated with a trend towards a reduced risk of clinical infections by herpesviruses as compared with non-users (OR 0.84; CI 95% 0.7-1.0;

Indexed as

BIFAPcase-control studyelectronic health care databaseherpesvirus infectionsvalproic acid

Identifiers

PMID31514402
PMCPMC6780826
OpenAlexW2972354214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.